XGXiaowen Guan

Xiaowen Guan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaowen Guan has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmaceutical Industry Perspectives on Exposure‐Response Confounding in Large Molecule Therapeutics: Results From an IQ Consortium Survey

    by Engie Salama, Manisha Lamba, Sihem Ait‐Oudhia, Ellen Wang, Dorothee Semiond, Zhang Li, Tao Long, Satyendra Suryawanshi, Leticia Arrington, Wei Gao, et al.

    Exposure‐response (ER) analyses assessing the efficacy of large molecule therapeutics are often susceptible to confounding, where associations between drug exposure and patient disease severity can obscure true ER signals and complicate dose selection. To better understand the pharmaceutical industry perspectives on this challenge, the IQ consortium conducted a comprehensive survey targeting clinical pharmacologists, pharmacometricians, and statisticians. The survey, completed by 125 individuals from 23 pharmaceutical companies, aimed to assess awareness, perceived prevalence, mitigation strategies, and the overall role of ER analyses in the context of confounding. Results revealed strong industry awareness, with 88.0% of respondents acknowledging the relevance of ER confounding. However, uncertainty regarding its pervasiveness persists, particularly in non‐oncology settings (31.2% unsure). A consensus emerged on the value of dose‐ranging study designs as an effective mitigation strategy (81.6% agreement). In contrast, the use of advanced statistical methods for causal inference is inconsistent (45.6% usage), and confidence in their reliability is mixed, with 32.8% of respondents expressing uncertainty and most others rating them only moderate or somewhat reliable. While the majority agreed that confounded ER analyses should be interpreted with caution (79.2%), opinions diverged regarding their value in decision‐making when dose‐ranging data is insufficient. This uncertainty, coupled with a recognized need for additional alignment with health authorities, led to a call for best‐practice guidance (92.8% view as valuable). Overall, the survey findings highlight a need for an industry‐wide common approach and the development of clear frameworks to manage and interpret ER confounding for large molecule therapeutics.

  • Open Access

    CD20×CD3 Bispecific Antibodies in B‐NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research

    by Min Zhu, Xiaowen Guan, Samit Ganguly, Erik Welf, John D. Davis

    Despite advancements in treatment for B‐cell non‐Hodgkin lymphoma (B‐NHL) in recent decades, many patients still relapse or are refractory to treatment, which represents a high unmet medical need. Novel CD20 × CD3 T‐cell–engaging bispecific antibodies (bsAbs) have created a new paradigm for the treatment of B‐NHL. Pivotal studies of four CD20 × CD3 bsAbs, mosunetuzumab, glofitamab, epcoritamab, and odronextamab, as monotherapy, have demonstrated robust responses with generally manageable safety profiles in patients with relapsed or refractory follicular lymphoma and diffuse large B‐cell lymphoma after ≥ 2 lines of systemic therapy. These agents have presented unique challenges (e.g., cytokine release syndrome [CRS]), which have required different strategies to overcome. This review provides a comprehensive overview of the clinical development of these four CD20 × CD3 bsAbs that have been investigated for the treatment of B‐NHL, with a specific focus on translational assessments to select starting doses in first‐in‐human studies, management of CRS, application of modeling and simulation approaches to aid dose escalation and optimization/selection, and strategies used in the design of phase I–III clinical trials. By highlighting learnings and experiences from these four bsAbs assessed, which have not been summarized collectively elsewhere, we aim to promote more efficient study design for novel bsAbs in B‐NHL in the future.


  • Top Cited Papers
    Open Access

    Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

    by John D. Davis, Marçal Bravo Padros, Daniela J. Conrado, Samit Ganguly, Xiaowen Guan, Hazem E. Hassan, Anasuya Hazra, Susan C. Irvin, Priya Jayachandran, Matthew P. Kosloski, et al.

    Subcutaneous (s.c.) administration of monoclonal antibodies (mAbs) can reduce treatment burden for patients and healthcare systems compared with intravenous (i.v.) infusion through shorter administration times, made possible by convenient, patient‐centric devices. A deeper understanding of clinical pharmacology principles related to efficacy and safety of s.c.‐administered mAbs over the past decade has streamlined s.c. product development. This review presents learnings from key constituents of the s.c. mAb development pathway, including pharmacology, administration variables, immunogenicity, and delivery devices. Restricted mAb transportation through the hypodermis explains their incomplete absorption at a relatively slow rate (pharmacokinetic (PK)) and may impact mAb‐cellular interactions and/or onset and magnitude of physiological responses (pharmacodynamic). Injection volumes, formulation, rate and site of injection, and needle attributes may affect PKs and the occurrence/severity of adverse events like injection‐site reactions or pain, with important consequences for treatment adherence. A review of immunogenicity data for numerous compounds reveals that incidence of anti‐drug antibodies (ADAs) is generally comparable across i.v. and s.c. routes, and complementary factors including response magnitude (ADA titer), persistence over time, and neutralizing antibody presence are needed to assess clinical impact. Finally, four case studies showcase how s.c. biologics have been clinically developed: (i) by implementation of i.v./s.c. bridging strategies to streamline PD‐1/PD‐L1 inhibitor development, (ii) through co‐development with i.v. presentations for anti‐severe acute respiratory syndrome‐coronavirus 2 antibodies to support rapid deployment of both formulations, (iii) as the lead route for bispecific T cell engagers (BTCEs) to mitigate BTCE‐mediated cytokine release syndrome, and (iv) for pediatric patients in the case of dupilumab.


  • Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study

    by Carla Biesdorf, Xiaowen Guan, Satya R. Siddani, David Hoffman, Nils Boehm, Bruno C. Medeiros, Toshihiko Doi, Maja de Jonge, Drew Rasco, Rajeev M. Menon, et al.

    Purpose Eftozanermin alfa is a second-generation tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist that enhances death receptor 4/5 clustering on tumor cells to induce apoptosis. We report the pharmacokinetics and immunogenicity of eftozanermin alfa administered intravenously to 153 adults with previously-treated solid tumors or hematologic malignancies from the first-in-human, open-label, dose-escalation and dose-optimization study. Methods Dose escalation evaluated eftozanermin alfa monotherapy 2.5–15 mg/kg on Day 1 or Days 1/8 of a 21-day cycle. Dose optimization evaluated eftozanermin alfa monotherapy or combination therapy with either oral venetoclax 400–800 mg daily (eftozanermin alfa 1.25–7.5 mg/kg Days 1/8/15 of a 21-day cycle) or chemotherapy (eftozanermin alfa 3.75 or 7.5 mg/kg Days 1/8/15/22 of a 28-day cycle and FOLFIRI regimen [leucovorin, 5-fluorouracil, and irinotecan] with/without bevacizumab on Days 1/15 of a 28-day cycle). Results Systemic exposures (maximum observed concentration [Cmax] and area under the concentration–time curve [AUC]) of eftozanermin alfa were approximately dose-proportional across the entire dose escalation range with minimal to no accumulation in Cycle 3 versus Cycle 1 exposures. Comparable exposures and harmonic mean half-lives (35.1 h [solid tumors], 31.3 h [hematologic malignancies]) were observed between malignancy types. Exposures (dose-normalized Cmax and AUC) in Japanese subjects were similar to non-Japanese subjects. Furthermore, eftozanermin alfa/venetoclax combination therapy did not have an impact on the exposures of either agent. Treatment-emergent anti-drug antibodies were observed in 9.4% (13/138) of subjects. Conclusions The study results, including a pharmacokinetic profile consistent with weekly dosing and low incidence of immunogenicity, support further investigation of eftozanermin alfa. Trial registration ID: NCT03082209.